Effect of Cornus mas L. on Cardiovascular disease in children

Effect of Cornus mas L. on Inflammatory Risk Factors, Lipid Profile and Apolipoproteins in Dyslipidemic Children

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT201206109662N3

Enrollment

Registered

2012-09-16

Start date

2011-08-29

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dyslipidemia. Endogenous hyperglyceridaemia Fredrickson's hyperlipoproteinaemia, type IV Hyperlipidaemia, group B Hyperprebetalipoproteinaemia Very-low-density-lipoprotein-type [VLDL] hyperlipoproteinaemia

Interventions

Intervention 1: case group: using 50 g of CM twice a day after the lunch and dinner. Intervention 2: case group:no treatment.

Prevention

Treatment - Drugs

case group: using 50 g of CM twice a day after the lunch and dinner

case group:no treatment

Eligibility

Sex/Gender

All

Age

9 Years to 16 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: subjects that had at least one of the dyslipidemic measures such as TG (=150 mg/dL), TC (=170 mg/dL), LDL (=130 mg/dL) and low HDL (<35 mg/dL) in serum; dyslipidemic children between the ages of 9-16 years. Exclusion criteria: known diabetes mellitus; liver disease; nephrotic syndrome; thyroid disorders; chronic pancreatitis; bile duct disorders; the use of medication that would alter lipid metabolism; the informed consent not being signed.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Total cholesterol. Timepoint: baseline and after the 3 and 6 wk of the treatment. Method of measurement: spectrophotometeric method.;Low-density lipoprotein. Timepoint: baseline and after the 3 and 6 wk of the treatment. Method of measurement: Friedewald formula.;High-density lipoprotein. Timepoint: baseline and after the 3 and 6 wk of the treatment. Method of measurement: spectrophotometeric method.;Triglyceride. Timepoint: baseline and after the 3 and 6 wk of the treatment. Method of measurement: spectrophotometeric method.	—

Measure

Time frame

Total cholesterol. Timepoint: baseline and after the 3 and 6 wk of the treatment. Method of measurement: spectrophotometeric method.;Low-density lipoprotein. Timepoint: baseline and after the 3 and 6 wk of the treatment. Method of measurement: Friedewald formula.;High-density lipoprotein. Timepoint: baseline and after the 3 and 6 wk of the treatment. Method of measurement: spectrophotometeric method.;Triglyceride. Timepoint: baseline and after the 3 and 6 wk of the treatment. Method of measurement: spectrophotometeric method.

—

Secondary

Measure	Time frame
WHR. Timepoint: baseline and after the 3 and 6 wk of the treatment. Method of measurement: tape.;BMI. Timepoint: baseline and after the 3 and 6 wk of the treatment. Method of measurement: tape.;VCAM. Timepoint: baseline and after the 3 and 6 wk of the treatment. Method of measurement: ELISA kit.;ICAM. Timepoint: baseline and after the 3 and 6 wk of the treatment. Method of measurement: ELISA kit.;CRP. Timepoint: baseline and after the 3 and 6 wk of the treatment. Method of measurement: automated chemistry analyzer.;Apo A. Timepoint: baseline and after the 3 and 6 wk of the treatment. Method of measurement: automated chemistry analyzer.;Apo B. Timepoint: baseline and after the 3 and 6 wk of the treatment. Method of measurement: automated chemistry analyzer.;HDL/LDL. Timepoint: baseline and after the 3 and 6 wk of the treatment. Method of measurement: spectrophotometeric method.;HDL/TC. Timepoint: baseline and after the 3 and 6 wk of the treatment. Method of measurement: spectrophotometeric method.	—

Measure

Time frame

WHR. Timepoint: baseline and after the 3 and 6 wk of the treatment. Method of measurement: tape.;BMI. Timepoint: baseline and after the 3 and 6 wk of the treatment. Method of measurement: tape.;VCAM. Timepoint: baseline and after the 3 and 6 wk of the treatment. Method of measurement: ELISA kit.;ICAM. Timepoint: baseline and after the 3 and 6 wk of the treatment. Method of measurement: ELISA kit.;CRP. Timepoint: baseline and after the 3 and 6 wk of the treatment. Method of measurement: automated chemistry analyzer.;Apo A. Timepoint: baseline and after the 3 and 6 wk of the treatment. Method of measurement: automated chemistry analyzer.;Apo B. Timepoint: baseline and after the 3 and 6 wk of the treatment. Method of measurement: automated chemistry analyzer.;HDL/LDL. Timepoint: baseline and after the 3 and 6 wk of the treatment. Method of measurement: spectrophotometeric method.;HDL/TC. Timepoint: baseline and after the 3 and 6 wk of the treatment. Method of measurement: spectrophotometeric method.

—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026